Find A Clinical Trial
Disease Type: Gynecologic
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
Principal Investigator
Alexander I. Spira, MD, PhD, FACP(ALKS 4230-007/GOG-3063) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
Principal Investigator
Robert L. Marsh, MDA Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN‑c3 in Combination with Niraparib in Subjects with Platinum-Resistant Ovarian Cancer
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma(FLORA-5)
Principal Investigator
Robert L. Marsh, MDA Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers).
Principal Investigator
Alexander I. Spira, MD, PhD, FACPPhase 2 Study of VS-6766 (Dual RAK/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
